DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study

Scott F. Huntington, Stephen J. Schuster, Wei Ding, Amber B. Koehler, Danielle M. Brander, Allison C. Rosenthal, Jose F. Leis, Han W. Tun, Muhamad Alhaj Moustafa, Madiha Iqbal, Wei He, Albert S. Kearney, Timothy P. McKinlay, Min Gui, Anthony R. Mato

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study'. Together they form a unique fingerprint.

Medicine & Life Sciences